
|Videos|July 30, 2019
Ovarian Cancer
Ovarian Cancer
Advertisement
Case: A 58-Year-Old Female With Progressive Ovarian Cancer
H & P
- A 58-year-old female presents to the clinic for bloating, pelvic pain, early satiety, and urinary urgency. She reports intolerance to strenuous activity at the gym for the past four months but is still able to carry out daily activities such as work, and house chores.
- PE: controlled HTN, abdominal distension;
- BP: 130/70 mmHg
- ECOG: 1
Imaging
- CT with contrast of the pelvis, abdomen, and chest reveals bilateral serous cystadenocarcinomas
Biopsy and Labs
- Pathology: high-grade serous carcinoma, epithelial ovarian cancer
- BRCA1-/2wt
- HRD/+
- CA-125: 280 U/mL
Treatment
- Diagnosis: stage IV ovarian cancer
- Patient underwent hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and tumor debulking
- Received IV paclitaxel and carboplatin and bevacizumab, 6 cycles
Follow-up
- CA-125, 43 U/mL upon completion of 6 cycles chemotherapy
- Ten months later at routine follow up, patient presented with recurring symptoms; CA-125, 565 U/mL
- Started on carboplatin/paclitaxel for 6 cycles plus bevacizumab
- Patient achieved a partial response, started on niraparib maintenance therapy
- Four months later:
- CBC: WNL, SCr: 0.8, AST: 10 u/L, ALT: 7 u/L, and ANC: 1.7 x 109/L
- BP, WNL
- ECOG 1
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































